In-hospital intervention, evidence-based pharmacotherapy and length of hospital stay comparing young (age ≤45 and older (age >45) with acute MI in the Malaysian NCVD-ACS registry from the year 2006 until year 2013
| Young women (n=182) N,% or mean± SD | Older women (n=2547) N,% or mean± SD | P value | |
| Thrombolysis | |||
| Given | 126 (69.2%) | 1742 (68.4%) | 0.400 |
| Not given – proceeded to PCI | 15 (8.2%) | 218 (8.6%) | |
| Not given – missed | 30 (16.5%) | 421 (16.5%) | |
| Not given – patient refusal | 3 (1.6%) | 14 (0.5%) | |
| Not given – contraindicated | 8 (4.4%) | 152 (6.0%) | |
| Door to needle time (minutes) | |||
| (Median +/−IQR) | 60 | 57 | <0.001 |
| Percutaneous coronary intervention | |||
| STEMI | 53 (29.3%) | 599 (24.5%) | 0.151 |
| NSTEMI | 17 (18.1%) | 381 (13.8%) | 0.244 |
| CABG Surgery | 1 (0.4%) | 56 (1.0%) | 0.160 |
| Evidence-based pharmacotherapy | |||
| Aspirin | 244 (92.4%) | 4187 (85.7%) | 0.002 |
| ADPA | 149 (72.0%) | 2671 (69.4%) | 0.437 |
| ACEI/ARB | 141 (49.3%) | 2639 (48.8%) | 0.864 |
| Beta blocker | 180 (69.5%) | 3070 (64.8%) | 0.120 |
| Statin | 234 (89.0%) | 4120 (84.9%) | 0.072 |
| Length of hospital stay (days) | 5.33±3.96 | 6.18±8.04 | 0.023 |
| Median +/−IQR | 4.00 (3.00, 5.75) | 4.00 (3.00, 6.00) | 0.035 |